Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Down – Here’s What Happened

Ono Pharmaceutical Co. (OTCMKTS:OPHLFGet Free Report)’s share price gapped down before the market opened on Monday . The stock had previously closed at $14.94, but opened at $14.15. Ono Pharmaceutical shares last traded at $14.15, with a volume of 200 shares.

Wall Street Analyst Weigh In

Separately, Zacks Research lowered Ono Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 4th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the company presently has a consensus rating of “Hold”.

View Our Latest Research Report on Ono Pharmaceutical

Ono Pharmaceutical Stock Down 5.7%

The firm has a fifty day simple moving average of $14.93 and a 200-day simple moving average of $14.64. The company has a market capitalization of $6.65 billion, a PE ratio of 13.48 and a beta of 0.33. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.86 and a current ratio of 3.28.

About Ono Pharmaceutical

(Get Free Report)

Ono Pharmaceutical Co, Ltd. is a Japanese research-driven pharmaceutical company headquartered in Osaka. The company discovers, develops, manufactures and markets prescription medicines, with a focus on oncology, immunology, neurology and other specialty-care areas. Its activities include both internally developed products and collaborations with pharmaceutical and biotechnology companies worldwide.

Ono is best known internationally for Opdivo (nivolumab), an immune checkpoint inhibitor developed in collaboration with Bristol Myers Squibb and used to treat multiple types of cancer.

Recommended Stories

Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.